There is a moment in every healthcare cycle where the market gets too focused on a single trial and misses everything else that is building underneath it.
That is where Gilead Sciences sits right now.
GILD is up roughly 3.5% this morning after a phase 3 HIV trial hit its key endpoints and Trodelvy won first-line approval for triple-negative breast cancer in both the U.S. and Europe. HSBC upgraded the stock to Buy just yesterday, raising its price target to $155 from $133. The upgrade thesis was pointed: HSBC argued that the market is being too pessimistic about Gilead’s HIV franchise, assuming a steeper decline from generic competition than the data actually supports. Long-acting HIV therapies, they argued, could offset much of that pressure through better patient adherence. The firm noted that roughly 60% of HIV patients have suboptimal adherence, and more than 40% take fewer than 80% of prescribed doses. A once-weekly or once-monthly regimen changes that math entirely.
Then there is Trodelvy. The FDA cleared it for first-line treatment of advanced triple-negative breast cancer. The European Commission granted similar approval across EU member states. The FDA and EC are now also reviewing a supplemental filing to pair Trodelvy with Keytruda for PD-L1 positive disease. If that combination clears, Gilead’s oncology positioning moves from peripheral to central. Trodelvy paired with Merck’s Keytruda is not a side hustle. That is a potential backbone therapy.
Gilead’s Q1 2026 results told a similar story: revenue of $6.96 billion, beating estimates by roughly 1.5%. Adjusted operating margin came in at 46.9%, well above expectations. The company raised full-year product sales guidance. The CEO described it as “the strongest pipeline in Gilead’s history.” That is not marketing language. The acquisitions of Arcellx, Ouro Medicines, and Tubulis are adding oncology assets with real near-term potential. Analysts maintain a Buy consensus with an average price target of $161.23 from 23 firms. The stock is trading near $129. That is a meaningful gap.
Now Regeneron.
REGN reported Q1 2026 revenues up 19% to $3.6 billion. Non-GAAP EPS of $9.47 beat estimates. Dupixent global net sales recorded by Sanofi grew 33% to $4.9 billion. EYLEA HD U.S. net sales surged 52% to $468 million. By the numbers, this is a company performing well. And yet the stock has fallen roughly 40% from its 52-week high of $821.
The reason is the pipeline.
Regeneron’s fianlimab and Libtayo combination failed to significantly delay cancer progression versus Merck’s Keytruda in a Phase 3 melanoma trial. That single result damaged confidence in one of the company’s core oncology bets. Citi downgraded to Neutral and cut its price target to $700 from $900. At least 10 brokerages reduced price targets after the update. The stock re-rated sharply lower, and it has not recovered.
The real debate with REGN is whether Dupixent can carry the company while the oncology pipeline rebuilds. Dupixent keeps expanding — it now covers chronic spontaneous urticaria in children aged 2 to 11, allergic fungal rhinosinusitis, and continues adding indications globally. The drug is still growing in the mid-30s percentage range annually. EYLEA HD is holding up better than feared despite biosimilar pressure. REGN has nearly 50 product candidates in clinical development. The pipeline is not empty.
But the melanoma setback matters. It reset the growth multiple and created real uncertainty about what comes next in oncology. That uncertainty is the overhang.
Valuation comparison: Gilead at $129 trades at roughly 17.9x earnings with a Buy consensus and a $161 average target. Regeneron trades in the $620 to $640 range following its drawdown, at roughly 17x to 18x earnings. Both are cheap for large-cap biopharma. But Gilead has the near-term catalysts — a July 9 non-Hodgkin lymphoma call, the Trodelvy EU combination filing, and an August 6 earnings date — and it has fresh institutional upgrades, not downgrades.
Regeneron’s Q2 earnings will be the real test of whether Dupixent growth can keep the financial model intact while management rebuilds oncology credibility. If it can, the stock at these levels may look like an obvious buy in hindsight. But that is a 12-month view, not a 30-day view.
The editorial call: Gilead is the stronger opportunity right now. The HSBC upgrade is specific, the Trodelvy approvals are real near-term revenue events, and the HIV long-acting therapy franchise is more durable than the market is pricing. Regeneron remains a high-quality business with a world-class Dupixent franchise, and patient investors may eventually be rewarded. But in this window, the momentum, the catalysts, and the analyst sentiment are all pointing toward Gilead — not Regeneron.
